Skip to main content
. Author manuscript; available in PMC: 2021 Jun 11.
Published in final edited form as: Ann Oncol. 2020 Jan;31(1):103–114. doi: 10.1016/j.annonc.2019.09.007

Table 1.

Baseline Characteristics of Studies included in the Pooled Analysis for Anthropometry and Risk of Prostate Cancer Incidence and Mortality

Prostate Cancer Cases (N)
Cohort1 Country Follow-up Time (Median) Baseline cohort size2,3 Median Age (Range), y Total Localized 4 Advanced5 Advanced (restricted)6 Protate Cancer Mortality 7 Low grade8 High grade9
ATBC Finland 1985-2002 (14) 26,963 49-70 (57) 1315 828 353 242 269 824 223
CARET USA 1985-2005 (12) 10,402 44-75 (57) 730 439 68 **10 **10 551 79
CLUE II USA 1989-2009 (19) 5,918 18-89 (51) 461 250 54 **10 **10 296 133
CPS II USA 1992-2005 (12) 65,021 42-93 (64) 6863 5722 451 276 279 5375 1221
COSM Sweden 1998-2008 (11) 43,010 45-79 (59) 2834 1774 513 381 293 1670 343
EPIC 10 European countries 1991-2006 (9) 142,174 20-97 (52) 2727 1337 345 175 248 1325 298
HPFS USA 1986-2008 (21) 46,648 32-79 (54) 5410 3798 651 313 518 4008 556
JPHC I Japan 1990-2008 (15) 20,016 40-59 (50) 135 78 **10 **10 **10 90 **10
JPHC II Japan 1993-2004 (12) 23,780 40-69 (54) 162 82 **10 **10 **10 90 **10
MCCS Australia 1990-2006 (13) 14,811 27-72 (55) 910 737 76 **10 70 668 218
MEC USA 1993-2004 (11) 83,591 45-78 (60) 5525 4549 508 365 280 3632 1553
NLCS Netherlands 1986-2007 2 (13) 58,279 54-70 (61) 2359 1231 733 544 450 1686 490
NIH-AARP USA 1995-2007 (10) 244,857 50-71 (62) 18497 13654 870 532 542 13463 3878
PCPT USA 1994-2003 (7) 15,462 55-86 (63) 846 786 **10 **10 **10 678 107
PLCO USA 1993-2008 (9) 29,840 55-75 (62) 2960 2543 140 87 78 2552 390
Total 830772 51734 36291 4762 2915 3027 36908 9489
1

ATBC= Alpha-Tocopherol Beta-Carotene Cancer Prevention Study, CARET=Beta-Carotene and Retinol Efficacy Trial , CLUE II=CLUE II: Campaign Against Cancer and Heart Disease, CPS II=Cancer Prevention Study II Nutrition Cohort, COSM=Cohort of Swedish Men, EPIC= European Prospective Investigation into Cancer and Nutrition, HPFS=Health Professionals Follow-up Study, JPHC I=The Japan Public Health Center-Based Study Cohort I, JPHC II=The Japan Public Health Center-Based Study Cohort II, MCCS=Melbourne Collaborative Cohort Study, MEC=Multiethnic Cohort, NLCS =Netherland Cohort Study, NIH-AARP=The NIH-AARP Diet and Health Study, PCPT=Prostate Cancer Prevention Trial, PLCO=Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial

2

Baseline cohort size and number of cases determined after applying exclusion criteria.

3

NLCS is analyzed as a case-cohort study so the baseline cohort size does not reflect the exclusions, and we did not supply a median follow-up time for the cohort.

4

”Localized”: defined as cancers with information on stage but are not defined as “periprostatic”, i.e. cancers confined within the prostate;

5

”Advanced”: defined as cancers with extension to or fixation to adjacent structures other than seminal vesicles, i.e. T4, N1, M1 or fatal;

6

”Advanced (restricted)”: same as “advanced” but excluding prostate cancer mortality cases that were initially diagnosed as localized cases or cases with missing stage information at diagnosis;

7

”Prostate Cancer Mortality”: defined when prostate cancer was the underlying cause of death

8

”Low grade”: Gleason score <8 or well/moderately differentiated;

9

”High grade”: Gleason score ≥8 or poorly differentiated/undifferentiated

10

Studies with less than 50 cases were excluded from the analysis of that prostate cancer outcome and is denoted by **